<DOC>
	<DOCNO>NCT02246621</DOCNO>
	<brief_summary>The main purpose study evaluate effective nonsteroidal aromatase inhibitor ( NSAI ) plus abemaciclib postmenopausal woman breast cancer . Participants randomize abemaciclib placebo 2:1 ratio .</brief_summary>
	<brief_title>A Study Nonsteroidal Aromatase Inhibitors Plus Abemaciclib ( LY2835219 ) Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Have diagnosis hormone receptorpositive ( HR+ ) , human epidermal growth factor receptor 2negative ( HER2 ) breast cancer Have locoregionally recurrent disease amenable resection radiation therapy curative intent metastatic disease Have postmenopausal status Have either measurable disease nonmeasurable boneonly disease Have performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale Have adequate organ function Have discontinue previous localize radiotherapy palliative purpose lytic lesion risk fracture prior randomization recover acute effect therapy Are able swallow capsule Have visceral crisis , lymphangitic spread , leptomeningeal carcinomatosis Have inflammatory breast cancer Have clinical evidence history central nervous system ( CNS ) metastasis Are currently receive previously receive endocrine therapy locoregionally recurrent metastatic breast cancer Have receive prior ( neo ) adjuvant endocrine therapy diseasefree interval ≤12 month completion treatment Are currently receive previously receive chemotherapy locoregionally recurrent metastatic breast cancer Have receive prior treatment everolimus Have receive prior treatment cyclindependent kinase ( CDK ) 4/6 inhibitor ( participated CDK4/6 inhibitor clinical trial treatment assignment still blind ) Have initiate bisphosphonates approve receptor activator nuclear factor kappaB ligand ( RANKL ) target agent &lt; 7 day prior randomization Are currently receive investigational drug clinical trial participate type medical research judge scientifically medically compatible study Have receive treatment drug receive regulatory approval indication within 14 21 day randomization nonmyelosuppressive myelosuppressive agent , respectively Have major surgery within 14 day prior randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MONARCH 3</keyword>
</DOC>